John P Geisler

Summary

Publications

  1. ncbi Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14261, USA
    Int J Cancer 113:782-8. 2005
  2. ncbi Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Cancer 98:2199-206. 2003
  3. ncbi Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival
    J P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, St Vincent Hospitals and Health Services, Indianapolis, IN 46260, USA
    Int J Gynecol Cancer 14:133-7. 2004
  4. ncbi Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer
    John P Geisler
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IO 52242, USA
    Gynecol Oncol 92:705-7. 2004
  5. ncbi Failure of BRCA1 dysfunction to alter ovarian cancer survival
    Richard E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospital and Clinic, Iowa City 52242 1009, USA
    Clin Cancer Res 8:1196-202. 2002
  6. ncbi Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Jeffrey L Hilton
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Iowa City, IA, USA
    J Natl Cancer Inst 94:1396-406. 2002
  7. ncbi Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma: a case-control analysis
    Melissa S Dunn
    Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA
    J Reprod Med 53:691-4. 2008
  8. ncbi Extreme drug resistance is common after prior exposure to paclitaxel
    John P Geisler
    Indiana Women s Oncology, Division of Gynecologic Oncology, St Vincent Hospitals Indianapolis, 8301 Harcourt Road, Suite 201, Indianapolis, Indiana, USA
    Gynecol Oncol 106:538-40. 2007
  9. ncbi Late recurrence of juvenile granulosa cell tumor of the ovary
    Stephen D Frausto
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA
    Am J Obstet Gynecol 191:366-7. 2004
  10. doi Robotically assisted laparoscopic radical hysterectomy compared with open radical hysterectomy
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo Medical Center, 3120 Glendale Ave, Mail Stop 1194, Toledo, OH 43614, USA
    Int J Gynecol Cancer 20:438-42. 2010

Collaborators

Detail Information

Publications25

  1. ncbi Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14261, USA
    Int J Cancer 113:782-8. 2005
    ..The metabonomic approach deserves further evaluation as a potential novel strategy for the early detection of epithelial ovarian cancer...
  2. ncbi Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA
    Cancer 98:2199-206. 2003
    ..The purpose of the current study was to determine the relation between MSI of ovarian carcinoma and MMR gene expression, hMLH1 and hMSH2 hypermethylation, and hMLH1 and hMSH2 null mutations...
  3. ncbi Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival
    J P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, St Vincent Hospitals and Health Services, Indianapolis, IN 46260, USA
    Int J Gynecol Cancer 14:133-7. 2004
    ..However, its role in endometrial cancer is essentially unknown. The objective of this study was to determine the relationship between cytoplasmic and nuclear c-myc staining, DNA index, and survival in patients with endometrial carcinoma...
  4. ncbi Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer
    John P Geisler
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IO 52242, USA
    Gynecol Oncol 92:705-7. 2004
    ..The second patient succumbed despite both aggressive supportive care and surgical intervention. Pathologic review for both patients revealed a drug induced vasculitis causing necrotizing enterocolitis...
  5. ncbi Failure of BRCA1 dysfunction to alter ovarian cancer survival
    Richard E Buller
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Iowa Hospital and Clinic, Iowa City 52242 1009, USA
    Clin Cancer Res 8:1196-202. 2002
    ..Many factors modify ovarian cancer survival. There are conflicting reports regarding survival of individuals with hereditary BRCA1-related ovarian cancer. None have controlled for other mechanisms of BRCA1 silencing in the control cohort...
  6. ncbi Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Jeffrey L Hilton
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, Iowa City, IA, USA
    J Natl Cancer Inst 94:1396-406. 2002
    ..Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression...
  7. ncbi Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma: a case-control analysis
    Melissa S Dunn
    Division of Gynecologic Oncology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA
    J Reprod Med 53:691-4. 2008
    ..To determine whether differences exist in clinicopathologic variables or survival between women with primary carcinoma of the fallopian tube (PCFT) and with epithelial ovarian carcinoma (EOC)...
  8. ncbi Extreme drug resistance is common after prior exposure to paclitaxel
    John P Geisler
    Indiana Women s Oncology, Division of Gynecologic Oncology, St Vincent Hospitals Indianapolis, 8301 Harcourt Road, Suite 201, Indianapolis, Indiana, USA
    Gynecol Oncol 106:538-40. 2007
    ..The purpose of this study was to determine on clinical samples whether a taxane-free interval (TFI), as defined by in vitro extreme drug resistance assay, existed in women previously exposed to platinum and taxane chemotherapy...
  9. ncbi Late recurrence of juvenile granulosa cell tumor of the ovary
    Stephen D Frausto
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA
    Am J Obstet Gynecol 191:366-7. 2004
    ..Late recurrences of JGCT can occur and continued close surveillance is recommended...
  10. doi Robotically assisted laparoscopic radical hysterectomy compared with open radical hysterectomy
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo Medical Center, 3120 Glendale Ave, Mail Stop 1194, Toledo, OH 43614, USA
    Int J Gynecol Cancer 20:438-42. 2010
    ..The purpose was to compare surgical and short-term outcomes, as well as margins, between robotic-assisted laparoscopic radical hysterectomy and open radical hysterectomy...
  11. doi Ovarian cancer risk assessment: a tool for preoperative assessment
    Deb A Ronco
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo Medical Center, 3120 Glendale Avenue, Mail Stop 1194, Toledo, OH 43614, United States
    Eur J Obstet Gynecol Reprod Biol 158:325-9. 2011
    ..The objective of this pilot study was to determine if the combination of CA 125, menopausal status and prealbumin can be used to accurately predict ovarian cancer in women with pelvic masses...
  12. ncbi Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer
    John P Geisler
    Indiana Women s Oncology, Indianapolis, IN 46260, USA
    Gynecol Oncol 106:128-31. 2007
    ..The purpose of this study was to determine if serum prealbumin could be used to objectively determine which patients could not safely undergo cytoreductive surgery...
  13. ncbi Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy
    Jeanne M Schilder
    Department of Ob Gyn, Division of Gynecologic Oncology, Indiana University Medical Center, 535 Barnhill Drive, Rm 436, Indianapolis, IN 46202 6294, USA
    Gynecol Oncol 87:1-7. 2002
    ..The purpose of this study was to determine the recurrence rate, survival, and pregnancy outcome in patients with Stage IA and Stage IC invasive epithelial ovarian cancer treated with unilateral adnexectomy...
  14. ncbi Imiquimod in vulvar Paget's disease: a case report
    John P Geisler
    Indiana Women s Oncology, Division of Gynecologic Oncology, St Vincent Hospitals, Indianapolis, IN 46260, USA
    J Reprod Med 53:811-2. 2008
    ..Vulvar Paget's disease is a relatively rare gynecologic neoplasm that is problematic because of its propensity to recur...
  15. ncbi Frequency of BRCA1 dysfunction in ovarian cancer
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    J Natl Cancer Inst 94:61-7. 2002
    ..Therefore, we developed an efficient strategy to detect various types of BRCA1 dysfunction and also determined the relative frequency of BRCA1 dysfunction in ovarian cancer...
  16. ncbi Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration
    John P Geisler
    Indiana Women s Oncology, University of Iowa Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, St Vincent Hospitals, 8301 Harcourt Road, Suite 201, Indianapolis, IN 46260, USA
    Gynecol Oncol 100:53-7. 2006
    ..To determine whether neoadjuvant cisplatin and 5-fluorouracil chemotherapy can be used to preserve the anal sphincter and/or urethra in patients with advanced vulvar cancer involving these sites...
  17. ncbi Recombinant factor VIIa to treat late radiation-induced hemorrhagic cystitis: a case report
    John P Geisler
    Division of Gynecologic Oncology, St Vincent Hospitals, Indianapolis, Indiana, USA
    J Reprod Med 53:360-2. 2008
    ..Late radiation cystitis is one of the most difficult complications of radiation therapy for pelvic malignancies...
  18. doi Robotically assisted total laparoscopic radical trachelectomy for fertility sparing in stage IB1 adenosarcoma of the cervix
    John P Geisler
    Division of Gynecologic Oncology, Indiana Women s Oncology, St Vincent Hospitals, Indianapolis, Indiana 46032, USA
    J Laparoendosc Adv Surg Tech A 18:727-9. 2008
    ..A 23-year-old woman was found to have a stage IB1 adenosarcoma of the cervix. She underwent a robotically assisted total laparoscopic radical trachelectomy with the placement of abdominal cerclage for the sparing of fertility...
  19. pmc Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
    Valerie A Allen
    Division of Gynecologic Oncology, Cancer Treatment Centers of America, Newnan, GA 30265, USA
    Case Rep Obstet Gynecol 2016:7540302. 2016
    ..Treatment must be sufficient to prevent relapses of the Clostridium difficile infection to prevent serious consequences in an already vulnerable patient population. ..
  20. pmc Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable?
    Natalie Klag
    Division of Gynecologic Oncology, Cancer Treatment Centers of America Newnan, Georgia, USA
    Clinicoecon Outcomes Res 8:287-91. 2016
    ..New chemotherapy combinations are being tested for the treatment of women with advanced, persistent or recurrent cervical cancer. We sought to evaluate the cost effectiveness of some newer combination therapies in cervical cancer...
  21. pmc Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis
    John P Geisler
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA
    J Cancer 3:454-8. 2012
    ..Trials have demonstrated improvements in survival with adding paclitaxel (P) or topotecan (T) to cisplatin (C) for the treatment of advanced cervical cancer. We sought to evaluate the cost effectiveness of these regimens...
  22. ncbi Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial
    Anil K Sood
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6080-5. 2004
    ..The purpose is to investigate the safety and efficacy of i.p. topotecan and oral etoposide as salvage treatment for patients with platinum-resistant ovarian or primary peritoneal cancer...
  23. ncbi Vascular endothelial growth factor staining and elevated INR in advanced epithelial ovarian carcinoma
    John P Geisler
    Indiana Women s Oncology, Division of Gynecologic Oncology, St Vincent Hospitals Indianapolis, Indiana USA
    J Surg Oncol 96:514-7. 2007
    ..4, in patients undergoing primary surgical cytoreduction for ovarian cancer...
  24. ncbi Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
    Thomas Clouse
    Gynecol Oncol 95:270-1. 2004
  25. ncbi Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?
    John P Geisler
    Gynecol Oncol 104:780-1. 2007